- Neuro-Oncology ClinicSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8th FloorNew Haven, CT 06511
- Smilow Cancer Hospital Care Center at TrumbullPark Avenue Medical Center5520 Park AvenueTrumbull, CT 06611
Nicholas Blondin, MD
Biography
Nicholas A. Blondin, MD, is a Yale Medicine neurologist who specializes in treating benign (noncancerous) and malignant (cancerous) brain tumors, brain and spine metastasis, and neurological symptoms of cancer such as seizures, cognitive impairment, headaches, gait disturbance, and weakness. He cares for patients at Smilow Cancer Hospital in New Haven and the Smilow Cancer Hospital Cancer Care Center in Trumbull.
“I love developing a strong doctor-patient relationship with my patients,” Dr. Blondin says. “I believe that a strong, trusting relationship is critical for me to help patients achieve their treatment goals and have the best possible quality of life.”
Dr. Blondin believes in “shared decision making,” a process he uses to create a treatment plan that will be best for each patient. “With a difficult diagnosis, I am open and honest but also work to provide hope that treatment will be effective,” Dr. Blondin says. “I let patients know that I will always be there for them, and I will support them in all phases of treatment.”
Together with a team of doctors at Smilow, he is able to help more patients achieve better outcomes. “In neuro-oncology, I rely on additional specialists such as neurosurgeons, radiation oncologists, pathologist, and neuro-radiologists in order to provide the best care for my patients,” he says.
Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center and is an assistant professor of clinical neurology at Yale School of Medicine.
Titles
- Associate Professor
Education & Training
- Chief ResidentYale School of Medicine (2012)
- ResidentYale School of Medicine (2011)
- InternYale School of Medicine (2009)
- MDUniversity of Connecticut School of Medicine
- BAWesleyan University, Chemistry
Additional Information
- Connecticut Brain Tumor Alliance Humanitarian Award: Connecticut Brain Tumor Alliance (2018)
- Cigna Care Designation: Cigna (2017)
- UnitedHealth Premium Designation, Quality & Cost Efficiency: UnitedHealthcare (2017)
- Palatucci Advocacy Leadership Forum Graduate: American Academy of Neurology (2014)
- Gold Humanism Honor Society: Yale School of Medicine (2013)
- Betsy Winters House Staff Award: Yale School of Medicine (2012)
- Power Day II Resident Award: Yale School of Medicine (2012)
- Lewis L. Levy Award in Neurology: Yale School of Medicine (2010)
- Power Day II Resident Award: Yale School of Medicine (2010)
- Schwartz Award: University of Connecticut School of Medicine (2007)
- United Council for Neurologic Subspecialties, Neuro-Oncology (2015, recertified: 2022)
- Yale University Protocol Review Committee (PRC) (2022 - Present): Committee Member
- Cancer Commons (2020 - 2023): Brain Cancer Advisory Board member, Cancer Commons
- Society for Neuro-Oncology (2020 - Present): Peer reviewer for SNO Annual Meeting
- Third Year Neurology Clerkship (2019 - Present): Instructor of Third Year Neurology Clerkship, Yale School of Medicine
- National Brain Tumor Society (2018 - Present): Head To The Hill, Advocate
- TS Alliance (2017 - 2018): Professional Advisory Board member, TS Alliance
- Musella Foundation (2017 - Present): Medical Advisory Board member, Musella Foundation
- St. Vincent's Brain Tumor Research Fund (2015 - 2018): Director of the St. Vincent's Brain Tumor Center Research Fund, with funding provided by the Connecticut Brain Tumor Alliance and individual donations
- Swim Across The Sound (2015 - Present): Participant in the St. Vincent's Swim Across The Sound marathon
- Connecticut Brain Tumor Alliance (2014 - Present): Medical Board member, Connecticut Brain Tumor Alliance
- Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.
- Perry J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelson T, Owen S, Mason W, Drappatz J, Blondin N, de Groot J. KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology 2024, 26: v5-v5. PMCID: PMC11485821, DOI: 10.1093/neuonc/noae144.013.
- Weller M, Berry D, Blondin N, Buxton M, Colman H, de Groot J, de la Fuente M, Ducray F, Ellingson B, Gordon G, Lassman A, Lee E, Lim M, Mellinghoff I, Perry J, Sulman E, Yung W, Wen P, Wick A, Cloughesy T. 500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Annals Of Oncology 2024, 35: s426-s427. DOI: 10.1016/j.annonc.2024.08.569.
- Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.
- de Groot J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelsen T, Owen S, Mason W, Drappatz J, Blondin N, Perry J. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Journal Of Clinical Oncology 2024, 42: 2005-2005. DOI: 10.1200/jco.2024.42.16_suppl.2005.
- Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.
- Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.
- Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.
- Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.
- Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.
- Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.
- Jin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis. Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.
- Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.
- Stuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER. Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.
- Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.
- Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.
- Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.
- Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.
- Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.
- Hong CS, Kuzmik GA, Kundishora AJ, Elsamadicy AA, Koo AB, McGuone D, Blondin NA, DiLuna ML, Erson-Omay EZ. Hypermutated phenotype in gliosarcoma of the spinal cord. Npj Precision Oncology 2021, 5: 8. PMID: 33580181, PMCID: PMC7881101, DOI: 10.1038/s41698-021-00143-w.
- Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.
- Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.
- Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.
- Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.
- Mayers M, Blondin N. Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases (P1.6-029). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p1.6-029.
- Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.
- Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.
- Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.
- Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.
- Jameyfield E, Blondin N. CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA. Neuro-Oncology 2017, 19: vi40-vi40. PMCID: PMC5691966, DOI: 10.1093/neuonc/nox168.156.
- Jameyfield E, Blondin N. Vismodegib Treatment of Intracranial Invasion of Basal Cell Carcinoma (P5.176). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p5.176.
- Jameyfield E, Blondin N. Generational Variance in Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 Mutation (P4.118). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p4.118.
- Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.
- Blondin N. ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.007.
- Blondin N. ATCT-06MANAGEMENT OF GLIOMATOSIS CEREBRI WITH TEMOZOLOMIDE AND TUMOR TREATING FIELDS. Neuro-Oncology 2015, 17: v2-v2. PMCID: PMC4638557, DOI: 10.1093/neuonc/nov206.06.
- Blondin N. MPTH-03IMPLEMENTATION AND UTILIZATION OF GENOMIC PROFILING IN A COMMUNITY NEURO-ONCOLOGY PRACTICE. Neuro-Oncology 2015, 17: v138-v138. PMCID: PMC4638974, DOI: 10.1093/neuonc/nov222.03.
- Blondin N, Baehring J, Hochberg F. Primary CNS Lymphoma. 2014, 308-315. DOI: 10.1002/9781118589199.ch48.
- Blondin NA. Diagnosis and management of periodic hypothermia. Neurology Clinical Practice 2014, 4: 26-33. PMID: 29473588, PMCID: PMC5765588, DOI: 10.1212/01.cpj.0000437350.47610.3a.
- Blondin NA, Becker KP. Anaplastic Gliomas Radiation, Chemotherapy, or Both? Hematology/Oncology Clinics Of North America 2012, 26: 811-823. PMID: 22794285, DOI: 10.1016/j.hoc.2012.04.003.
- Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009). Neurology 2012, 78: in7-1.009-in7-1.009. DOI: 10.1212/wnl.78.1_meetingabstracts.in7-1.009.
- Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148). Neurology 2012, 78: p07.148-p07.148. DOI: 10.1212/wnl.78.1_meetingabstracts.p07.148.
- Hernandez AL, Blondin NA, Curiale G, Greer DM. Plantar Flexion with Noxious Dorsal Foot Stimulation in Brain Death. Neurocritical Care 2012, 17: 268-270. PMID: 22528275, DOI: 10.1007/s12028-012-9697-x.
- Blondin NA, Vortmeyer AO, Harel NY. Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic Encephalitis. JAMA Neurology 2011, 68: 1591-1594. PMID: 22159058, DOI: 10.1001/archneurol.2011.876.
- Blondin NA, Huttner A, Baehring JM. Unilateral Tongue Atrophy and Fasciculation. JAMA Neurology 2011, 68: 1478-1478. PMID: 22084136, DOI: 10.1001/archneurol.2011.652.
- Sawires M, Berek K, Blondin N, Schindler J. First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 77: 1019. PMID: 21893675, DOI: 10.1212/wnl.0b013e31822470d4.
- Blondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.
- Blondin NA, Schindler JL. Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 76: e14. PMID: 21263131, DOI: 10.1212/wnl.0b013e31820882db.
- Blondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.
- Blondin NA, Zahedi S, Hale MS. A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome. The Primary Care Companion For CNS Disorders 2008, 10: 249-50. PMID: 18615175, PMCID: PMC2446496, DOI: 10.4088/pcc.v10n0312b.
- Carson JH, Blondin N, Korza G. Rules of engagement promote polarity in RNA trafficking. BMC Neuroscience 2006, 7: s3. PMID: 17118157, PMCID: PMC1775043, DOI: 10.1186/1471-2202-7-s1-s3.
- Neuro-Oncology ClinicSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8th FloorNew Haven, CT 06511
- Smilow Cancer Hospital Care Center at TrumbullPark Avenue Medical Center5520 Park AvenueTrumbull, CT 06611
Biography
Nicholas A. Blondin, MD, is a Yale Medicine neurologist who specializes in treating benign (noncancerous) and malignant (cancerous) brain tumors, brain and spine metastasis, and neurological symptoms of cancer such as seizures, cognitive impairment, headaches, gait disturbance, and weakness. He cares for patients at Smilow Cancer Hospital in New Haven and the Smilow Cancer Hospital Cancer Care Center in Trumbull.
“I love developing a strong doctor-patient relationship with my patients,” Dr. Blondin says. “I believe that a strong, trusting relationship is critical for me to help patients achieve their treatment goals and have the best possible quality of life.”
Dr. Blondin believes in “shared decision making,” a process he uses to create a treatment plan that will be best for each patient. “With a difficult diagnosis, I am open and honest but also work to provide hope that treatment will be effective,” Dr. Blondin says. “I let patients know that I will always be there for them, and I will support them in all phases of treatment.”
Together with a team of doctors at Smilow, he is able to help more patients achieve better outcomes. “In neuro-oncology, I rely on additional specialists such as neurosurgeons, radiation oncologists, pathologist, and neuro-radiologists in order to provide the best care for my patients,” he says.
Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center and is an assistant professor of clinical neurology at Yale School of Medicine.
Titles
- Associate Professor
Education & Training
- Chief ResidentYale School of Medicine (2012)
- ResidentYale School of Medicine (2011)
- InternYale School of Medicine (2009)
- MDUniversity of Connecticut School of Medicine
- BAWesleyan University, Chemistry
Additional Information
- Connecticut Brain Tumor Alliance Humanitarian Award: Connecticut Brain Tumor Alliance (2018)
- Cigna Care Designation: Cigna (2017)
- UnitedHealth Premium Designation, Quality & Cost Efficiency: UnitedHealthcare (2017)
- Palatucci Advocacy Leadership Forum Graduate: American Academy of Neurology (2014)
- Gold Humanism Honor Society: Yale School of Medicine (2013)
- Betsy Winters House Staff Award: Yale School of Medicine (2012)
- Power Day II Resident Award: Yale School of Medicine (2012)
- Lewis L. Levy Award in Neurology: Yale School of Medicine (2010)
- Power Day II Resident Award: Yale School of Medicine (2010)
- Schwartz Award: University of Connecticut School of Medicine (2007)
- United Council for Neurologic Subspecialties, Neuro-Oncology (2015, recertified: 2022)
- Yale University Protocol Review Committee (PRC) (2022 - Present): Committee Member
- Cancer Commons (2020 - 2023): Brain Cancer Advisory Board member, Cancer Commons
- Society for Neuro-Oncology (2020 - Present): Peer reviewer for SNO Annual Meeting
- Third Year Neurology Clerkship (2019 - Present): Instructor of Third Year Neurology Clerkship, Yale School of Medicine
- National Brain Tumor Society (2018 - Present): Head To The Hill, Advocate
- TS Alliance (2017 - 2018): Professional Advisory Board member, TS Alliance
- Musella Foundation (2017 - Present): Medical Advisory Board member, Musella Foundation
- St. Vincent's Brain Tumor Research Fund (2015 - 2018): Director of the St. Vincent's Brain Tumor Center Research Fund, with funding provided by the Connecticut Brain Tumor Alliance and individual donations
- Swim Across The Sound (2015 - Present): Participant in the St. Vincent's Swim Across The Sound marathon
- Connecticut Brain Tumor Alliance (2014 - Present): Medical Board member, Connecticut Brain Tumor Alliance
- Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.
- Perry J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelson T, Owen S, Mason W, Drappatz J, Blondin N, de Groot J. KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology 2024, 26: v5-v5. PMCID: PMC11485821, DOI: 10.1093/neuonc/noae144.013.
- Weller M, Berry D, Blondin N, Buxton M, Colman H, de Groot J, de la Fuente M, Ducray F, Ellingson B, Gordon G, Lassman A, Lee E, Lim M, Mellinghoff I, Perry J, Sulman E, Yung W, Wen P, Wick A, Cloughesy T. 500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Annals Of Oncology 2024, 35: s426-s427. DOI: 10.1016/j.annonc.2024.08.569.
- Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.
- de Groot J, Cloughesy T, Berry D, Buxton M, Colman H, Ellingson B, Gordon G, Lassman A, Lim M, Mellinghoff I, Sulman E, Weller M, Wen P, Hyddmark E, Mikkelsen T, Owen S, Mason W, Drappatz J, Blondin N, Perry J. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Journal Of Clinical Oncology 2024, 42: 2005-2005. DOI: 10.1200/jco.2024.42.16_suppl.2005.
- Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.
- Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.
- Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.
- Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.
- Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.
- Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.
- Jin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis. Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.
- Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.
- Stuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER. Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.
- Blondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.
- Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.
- Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.
- Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.
- Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.
- Hong CS, Kuzmik GA, Kundishora AJ, Elsamadicy AA, Koo AB, McGuone D, Blondin NA, DiLuna ML, Erson-Omay EZ. Hypermutated phenotype in gliosarcoma of the spinal cord. Npj Precision Oncology 2021, 5: 8. PMID: 33580181, PMCID: PMC7881101, DOI: 10.1038/s41698-021-00143-w.
- Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.
- Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.
- Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.
- Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.
- Mayers M, Blondin N. Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases (P1.6-029). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p1.6-029.
- Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.
- Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.
- Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.
- Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.
- Jameyfield E, Blondin N. CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA. Neuro-Oncology 2017, 19: vi40-vi40. PMCID: PMC5691966, DOI: 10.1093/neuonc/nox168.156.
- Jameyfield E, Blondin N. Vismodegib Treatment of Intracranial Invasion of Basal Cell Carcinoma (P5.176). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p5.176.
- Jameyfield E, Blondin N. Generational Variance in Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 Mutation (P4.118). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p4.118.
- Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.
- Blondin N. ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.007.
- Blondin N. ATCT-06MANAGEMENT OF GLIOMATOSIS CEREBRI WITH TEMOZOLOMIDE AND TUMOR TREATING FIELDS. Neuro-Oncology 2015, 17: v2-v2. PMCID: PMC4638557, DOI: 10.1093/neuonc/nov206.06.
- Blondin N. MPTH-03IMPLEMENTATION AND UTILIZATION OF GENOMIC PROFILING IN A COMMUNITY NEURO-ONCOLOGY PRACTICE. Neuro-Oncology 2015, 17: v138-v138. PMCID: PMC4638974, DOI: 10.1093/neuonc/nov222.03.
- Blondin N, Baehring J, Hochberg F. Primary CNS Lymphoma. 2014, 308-315. DOI: 10.1002/9781118589199.ch48.
- Blondin NA. Diagnosis and management of periodic hypothermia. Neurology Clinical Practice 2014, 4: 26-33. PMID: 29473588, PMCID: PMC5765588, DOI: 10.1212/01.cpj.0000437350.47610.3a.
- Blondin NA, Becker KP. Anaplastic Gliomas Radiation, Chemotherapy, or Both? Hematology/Oncology Clinics Of North America 2012, 26: 811-823. PMID: 22794285, DOI: 10.1016/j.hoc.2012.04.003.
- Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009). Neurology 2012, 78: in7-1.009-in7-1.009. DOI: 10.1212/wnl.78.1_meetingabstracts.in7-1.009.
- Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148). Neurology 2012, 78: p07.148-p07.148. DOI: 10.1212/wnl.78.1_meetingabstracts.p07.148.
- Hernandez AL, Blondin NA, Curiale G, Greer DM. Plantar Flexion with Noxious Dorsal Foot Stimulation in Brain Death. Neurocritical Care 2012, 17: 268-270. PMID: 22528275, DOI: 10.1007/s12028-012-9697-x.
- Blondin NA, Vortmeyer AO, Harel NY. Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic Encephalitis. JAMA Neurology 2011, 68: 1591-1594. PMID: 22159058, DOI: 10.1001/archneurol.2011.876.
- Blondin NA, Huttner A, Baehring JM. Unilateral Tongue Atrophy and Fasciculation. JAMA Neurology 2011, 68: 1478-1478. PMID: 22084136, DOI: 10.1001/archneurol.2011.652.
- Sawires M, Berek K, Blondin N, Schindler J. First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 77: 1019. PMID: 21893675, DOI: 10.1212/wnl.0b013e31822470d4.
- Blondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.
- Blondin NA, Schindler JL. Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 76: e14. PMID: 21263131, DOI: 10.1212/wnl.0b013e31820882db.
- Blondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.
- Blondin NA, Zahedi S, Hale MS. A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome. The Primary Care Companion For CNS Disorders 2008, 10: 249-50. PMID: 18615175, PMCID: PMC2446496, DOI: 10.4088/pcc.v10n0312b.
- Carson JH, Blondin N, Korza G. Rules of engagement promote polarity in RNA trafficking. BMC Neuroscience 2006, 7: s3. PMID: 17118157, PMCID: PMC1775043, DOI: 10.1186/1471-2202-7-s1-s3.
- Neuro-Oncology ClinicSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8th FloorNew Haven, CT 06511
- Smilow Cancer Hospital Care Center at TrumbullPark Avenue Medical Center5520 Park AvenueTrumbull, CT 06611
- Neuro-Oncology ClinicSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8th FloorNew Haven, CT 06511
- Smilow Cancer Hospital Care Center at TrumbullPark Avenue Medical Center5520 Park AvenueTrumbull, CT 06611